Structured around development of novel therapeutics for age-related degenerative disease, AgeX is applying a proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology. Before its own public offering in November 2018, Agex operated as a subsidiary of BioTime, Inc. (NYSE: BTX). The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety.
